American Association for Cancer Research
Best Practices in Lung Cancer – November 2018 Vol 9 | November 29, 2018
The combination of nivolumab plus ipilimumab extended progression-free survival (PFS) versus standard chemotherapy as first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) with a high tumor mutational burden (TMB).
Best Practices in Lung Cancer – November 2018 Vol 9 | November 29, 2018
A burning question is whether immunotherapy combinations will further improve outcomes over checkpoint inhibitor therapy alone; and if so, which combinations will rise to the top.
June 2016 Vol 7, No 5 | June 7, 2016
Targeted therapies used to treat hematologic malignancies can cause unintended cardiac toxicity in some patients and can lead to cardiac-related mortality, according to study results presented at the American Association for Cancer Research Annual Meeting.
Results 1 - 3 of 3